Characterization of ROS1 cDNA from a human glioblastoma cell line
about
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinaseScatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptorAn analysis of vertebrate mRNA sequences: intimations of translational controlALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceROS1 rearrangements define a unique molecular class of lung cancers.PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKComparison of the sevenless genes of Drosophila virilis and Drosophila melanogaster.Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.Activated RET and ROS: two new driver mutations in lung adenocarcinoma.The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.Lack of ROS1 Gene Rearrangement in Glioblastoma MultiformeSynergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma.Cancer genes in lung cancer: racial disparities: are there any?Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth.Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros.Enhancement of transforming potential of human insulinlike growth factor 1 receptor by N-terminal truncation and fusion to avian sarcoma virus UR2 gag sequence.Importance of receptor occupancy, concentration differences, and ligand exchange in the insulin-like growth factor I receptor system.ROS1 expression in invasive ductal carcinoma of the breast related to proliferation activity.Personalizing therapy in advanced non-small cell lung cancerBenefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.Evidence for the identity of human scatter factor and human hepatocyte growth factor.ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.The Drosophila insulin receptor contains a novel carboxyl-terminal extension likely to play an important role in signal transduction.EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis.ROS1 fusions in cancer: a review.Lung cancer as a paradigm for precision oncology in solid tumours.Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 Is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts.The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation.Transient and locally restricted expression of the ros1 protooncogene during mouse development.Mutations of Ros differentially effecting signal transduction pathways leading to cell growth versus transformation.The ortholog of the human proto-oncogene ROS1 is required for epithelial development in C. elegans.
P2860
Q24310364-E6DAE28E-AFEA-4BB6-9681-04663000642BQ24564783-234E27D2-9787-48C1-A998-5FD327290DDAQ24642530-F6B751D2-0ED5-4135-89B9-9A4D9321C92BQ26775347-15902C7C-6260-4601-BA85-056ABE0ACF96Q27851700-AD054D06-238A-4E35-A222-BB265C013E94Q27853138-65524AC0-B4BE-4372-AADE-7E586CD81E93Q28083446-E716B4C0-E0DD-439F-89DC-A7528D8BC32AQ33688110-24A2FC67-6910-4B1E-93C4-83B1EF0D9985Q35080328-34A470D1-B15F-4143-8F77-FACDE83797C0Q35206630-C6E9EB84-4AA4-45AF-A579-85F04DEC5E84Q35532823-FE22C6B7-7F5B-448A-9266-2ABC294DE1ABQ35772397-F0582343-5D75-4ECC-80BA-D9099D14DB1EQ36341179-03675058-9943-4C80-AA9E-E9708F1469ACQ36481954-F4FA3AF3-188E-4713-92B7-621C7C4E0748Q36558015-3D4B72C3-BCD8-4EC5-B7ED-1D4DB460984FQ36654236-31EE780C-ECBE-48D2-9C07-D48FFD2082E3Q36656168-FB1E0772-D2B4-434D-976C-9627CD6C231AQ36707260-C4580390-BD81-4F70-A73C-A6B056D944D8Q36793176-6C4C7EAB-A323-41AE-919D-A3A525614BB3Q36811453-A8A50181-69CE-489E-B119-26D9E8134C19Q37162291-4E668F46-B270-4406-B232-00E8FD8B266BQ37574028-8B52AC39-8C8A-4499-A4BE-08A4C8F93366Q38002468-5CC9388B-2D33-4AEF-9723-437B260B8D31Q38297918-3FB919EB-F464-4285-9453-00D9EF51E2CEQ38651948-BD33AF9F-F895-4702-A6F2-04A965F4660FQ38852070-DB7387BB-1CA2-42DA-8086-85DE3DB41A4BQ39449763-B8B69822-9037-49FF-B778-D5ABA7FB5993Q40662629-FB82D991-378F-47FD-83F0-832E90026ACDQ40756384-028AFF21-5870-40B5-A4BC-871F58663F1CQ41083296-F6FB4D82-36B6-47D8-B18E-E46CFCF919F0Q41133992-11664E5F-BDAF-4788-BA47-FD857026C4E7Q42032097-1E170FEE-4C85-47C3-8D97-9D0E6F77A3AB
P2860
Characterization of ROS1 cDNA from a human glioblastoma cell line
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Characterization of ROS1 cDNA from a human glioblastoma cell line
@ast
Characterization of ROS1 cDNA from a human glioblastoma cell line
@en
Characterization of ROS1 cDNA from a human glioblastoma cell line
@nl
type
label
Characterization of ROS1 cDNA from a human glioblastoma cell line
@ast
Characterization of ROS1 cDNA from a human glioblastoma cell line
@en
Characterization of ROS1 cDNA from a human glioblastoma cell line
@nl
prefLabel
Characterization of ROS1 cDNA from a human glioblastoma cell line
@ast
Characterization of ROS1 cDNA from a human glioblastoma cell line
@en
Characterization of ROS1 cDNA from a human glioblastoma cell line
@nl
P2093
P2860
P3181
P356
P1476
Characterization of ROS1 cDNA from a human glioblastoma cell line
@en
P2093
P2860
P304
P3181
P356
10.1073/PNAS.87.12.4799
P407
P577
1990-06-01T00:00:00Z